SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...
Millions of Brits can skip the GP queue this winter and head straight to their local pharmacist. Amid warnings a ‘quad-emic’ of flu, covid, RSV and norovirus, doctors and hospital medics are battling ...
Clarametyx Biosciences Inc. ("Clarametyx"), a biotechnology company developing immune-enabling biologic technologies to combat serious infections associated with biofilms, today announced that CARB-X ...
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...